ANKRD36: A Potential Drug Target and Biomarker for Ankylosing Spondylitis

Target Name: ANKRD36

NCBI ID: G375248

ANKRD36

ANKRD36: A Potential Drug Target and Biomarker for Ankylosing Spondylitis

Ankylosing spondylitis (AS) is a chronic progressive autoimmune disorder characterized by inflammation and damage to the spinal column. It is a leading cause of lower back pain and stiffness, and can also cause significant functional limitations. While there are several medications available to treat AS, the disease remains a chronic and life-altering condition, and there is a need for more effective and targeted treatments.

The ANKRD36 gene, which encodes a protein known as ANKRD36, has recently been identified as a potential drug target and biomarker for AS. ANKRD36 is a protein that is expressed in the articular cartilage of individuals with AS and has been shown to play a role in the development and progression of the disease.

The ANKRD36 protein is involved in the regulation of cell signaling pathways that are important for the development and maintenance of cartilage. It is part of a family of proteins known as the ANKRD gene family, which is characterized by the presence of a specific domain called the ANKRD36 gene. This domain is unique in that it contains a conserved heptadecapeptide sequence that is highly conserved across different species, including humans.

The ANKRD36 gene has been shown to be involved in the regulation of several key signaling pathways that are important for the development and maintenance of cartilage. One of these pathways is the TGF-β pathway, which is a well-known regulator of cell signaling that is involved in the development and maintenance of tissues and organs, including cartilage.

The TGF-β pathway is a complex signaling pathway that is involved in the regulation of cell proliferation, differentiation, and inflammation. It is a critical pathway for the development and maintenance of tissues and organs, including cartilage, and is often targeted by drugs that are used to treat various diseases, including AS.

The ANKRD36 protein is shown to be involved in the regulation of TGF-β signaling in AS. Several studies have shown that ANKRD36 is expressed in the articular cartilage of individuals with AS and that it is involved in the regulation of TGF-β signaling in this tissue. Additionally, several studies have shown that inhibiting ANKRD36 activity can reduce inflammation and pain in individuals with AS.

The ANKRD36 protein is also involved in the regulation of another important signaling pathway called the NF-kappa-B pathway. NF-kappa-B is a signaling pathway that is involved in the regulation of inflammation and pain. It is a critical pathway for the development and maintenance of tissues and organs, including the articular cartilage, and is often targeted by drugs that are used to treat various diseases, including AS.

The ANKRD36 protein is shown to be involved in the regulation of NF-kappa-B signaling in AS. Several studies have shown that ANKRD36 is expressed in the articular cartilage of individuals with AS and that it is involved in the regulation of NF-kappa-B signaling in this tissue. Additionally, several studies have shown that inhibiting ANKRD36 activity can reduce inflammation and pain in individuals with AS.

In conclusion, ANKRD36 is a protein that is expressed in the articular cartilage of individuals with AS and has been shown to play a role in the development and progression of the disease. The ANKRD36 protein is involved in several key signaling pathways, including the TGF-β and NF-kappa-B pathways, and is a potential drug target and biomarker for AS. Further research is needed to fully understand the role of ANKRD36 in AS and to develop effective treatments for this disease.

Protein Name: Ankyrin Repeat Domain 36

The "ANKRD36 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ANKRD36 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets